Key facts
- Akagera Medicines’s last known valuation is $345.0M (Jan 2025).
- It has raised $62.2M; the latest was Later Stage VC ($30.0M) in Jan 2025.
- Notable investors include Coalition for Epidemic Preparedness Innovations, Crocker Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Akagera Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Akagera Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Akagera Medicines
Developer of novel liposomal formulations of antibacterial drugs intended to treat tuberculosis. The company develops novel liposomal formulations of antibacterial drugs to treat tuberculosis and other infectious diseases in macrophages responsible for phagocytosis, enabling patients to get the treatment for tuberculosis, eliminating toxicity, and lowering the costs to patients and society.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2018
- Employees
- 16
- Website
- akageramedicines.com/
- Ownership
- Privately Held (backing)
Akagera Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akagera Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akagera Medicines in its N-PORT filings yet. We sweep new filings monthly.